Sign inJoin waitlistJoin the waitlist

MI

Michael Isakoff

Interim Chair, Department of Pediatrics · University of Connecticut School of Medicine

Credentials: · · · ·

History

Department of Pediatrics · University of Connecticut School of Medicine
Present

Boston Children's Hospital Neonatal Perinatal Fellowship Program
2002–2003
Pediatrics
Yale-New Haven Hospital
1999–2002
New York University Grossman School of Medicine
1995–1999

Research

Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Review · Journal of Clinical Oncology · 2015 · First of 4 authors · 1,275 citations
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
European Journal of Cancer · 2019 · 537 citations
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international,…
The Lancet Oncology · 2016 · 422 citations

DR
Damon Reed
12 papers
Katherine Janeway
11 papers
Richard Gorlick
11 papers
Masanori Hayashi
8 papers
David Loeb
7 papers
Lars Wagner
7 papers
Jacqueline Kraveka
6 papers
Javier Oesterheld
6 papers
Robert Goldsby
6 papers
Scott Borinstein
6 papers
Steven DuBois
6 papers
William Ferguson
6 papers

Clinical trials

Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2014–2020
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Site PI · Recruiting · Phase 1, Phase 2
Milton S. Hershey Medical Center
2026–2035
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Site PI · Recruiting · Phase 1
H. Lee Moffitt Cancer Center and Research Institute
2026–2030